Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Despite having adopted preventive measures, tuberculosis (TB) may still occur in patients with inflammatory bowel disease (IBD) treated with anti-tumour necrosis factor (anti-TNF). Data on the causes and characteristics of TB cases in this scenario are lacking. Our aim was to describe the characteristics of TB in anti-TNF-treated IBD patients after the publication of the Spanish TB prevention guidelines in IBD patients and to evaluate the safety of restarting anti-TNF after a TB diagnosis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Crohns Colitis

Title: Journal of Crohn's & colitis

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1876-4479

ISSN (Print): 1873-9946

Publication date (Electronic): Oct 2016

Volume: 10

Issue: 10

Affiliations

[1 ] Complexo Hospitalario Universitario de Pontevedra. Instituto de Investigación Biomédica Galicia Sur (IBI), Spain daniel.carpio.lopez@sergas.es.

[2 ] Hospital Clinic i Provincial, Barcelona, Spain.

[3 ] Hospital Central de Asturias, Oviedo, Spain.

[4 ] Complexo Hospitalario Universitario, Vigo, Spain.

[5 ] Complexo Hospitalario Universitario, Santiago de Compostela, Spain.

[6 ] Hospital Clínico, Madrid, Spain.

[7 ] Hospital de Badalona, Barcelona, Spain.

[8 ] Hospital Universitario Arquitecto Marcide, Ferrol, Spain.

[9 ] Hospital Universitario Marqués de Valdecilla, Santander, Spain.

[10 ] Complexo Universitario Juan Canalejo, A Coruña, Spain.

[11 ] Hospital Virgen de Altagracia, Manzanares, Ciudad Real, Spain.

[12 ] Complejo Hospitalario, León, Spain.

[13 ] Hospital Rio Hortega, Valladolid, Spain.

[14 ] Hospital Infanta Cristina de Parla, Madrid, Spain.

[15 ] Clínica Puerta de Hierro, Madrid, Spain.

[16 ] Servicio de Aparato Digestivo, Hospital Universitario de La Princesa e Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.

[17 ] Hospital Son Espases, Palma de Mallorca, Spain.

[18 ] Hospital de Fuenlabrada, Madrid, Spain.

[19 ] Hospital de Manises, Valencia, Spain.

[20 ] Institut Universitàri Parc Taulí, Sabadell, Spain.

[21 ] Complexo Hospitalario Universitario de Pontevedra. Instituto de Investigación Biomédica Galicia Sur (IBI), Spain.

[22 ] Hospital Santa Creu i Sant Pau, Barcelona, Spain.

[23 ] Hospital de Valme, Sevilla, Spain.

Article

Publisher Item ID: jjw022

DOI: 10.1093/ecco-jcc/jjw022

PubMed ID: 26802085

SO-VID: 48c71711-efb4-4e0d-b76a-50c219016bab

History

Keywords: Anti-TNF,ulcerative colitis,tuberculosis,retreatment,prevention,infliximab,inflammatory bowel disease,adalimumab,Crohn’s disease

Data availability:

Keywords: Anti-TNF, ulcerative colitis, tuberculosis, retreatment, prevention, infliximab, inflammatory bowel disease, adalimumab, Crohn’s disease

Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.

Read this article at

Abstract

Related collections

Karger: Gastroenterology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 333

Cited by 10